New Formulations for Diagnosis of Alzheimer's Disease

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention provides a new method and diagnostic kit for early and reliable detection of Alzheimer's disease by measuring and analyzing the ratio of two specific amyloid beta peptides (Aß(1-42), Aß(2-40), and Aß(2-42)) in a bodily fluid sample, particularly blood plasma or serum. The method offers a comparatively less invasive, more patient-friendly, and more accurate approach than traditional cerebrospinal fluid (CSF)-based or imaging diagnostics. The result helps identify both preclinical and early stages of Alzheimer's, thereby allowing earlier intervention and disease management.

Use CasesContent extracted from patent full text and abstract with AI.

• Routine screening for Alzheimer’s risk in the elderly population using blood tests.
• Early-stage diagnosis of Alzheimer’s in patients with mild cognitive impairment (MCI) for proactive care planning.
• Differential diagnosis to distinguish Alzheimer’s disease from other forms of dementia using blood biomarkers.
• Monitoring the progression of Alzheimer’s disease and tracking response to therapeutic interventions.
• Population-level Alzheimer’s risk assessment in research or clinical epidemiological studies.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables much earlier detection of Alzheimer's disease, including preclinical and prodromal stages, which are not reliably caught by existing methods.
• Minimally invasive sample collection via blood/plasma, avoiding the risks, discomfort, and expense of CSF taps or frequent imaging.
• Higher specificity and sensitivity for Alzheimer’s diagnosis than currently used blood-based markers or imaging approaches.
• Facilitates repeated, standardized, and scalable testing suitable for both clinical and large-scale screening scenarios.
• Supports tailored preventive or disease-modifying interventions through reliable risk assessment and disease monitoring.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to the use of at least one quantitative ratio (quotient) of two amyloid beta peptidea (A beta; Aß) which are different from one another in a sample of a bodily fluid of a test subject and/or patient in order to determine the probability (risk) of said test subject and/or patient suffering Alzheimer's disease (Morbus Alzheimer, AD) and/or to determine (diagnose) suffering from an early stage of Alzheimer's disease, wherein the amyloid beta peptides are selected from (a) Aß(1-42), (b) Aß(2-40) and (c) Aß(2-42) and wherein the quantitative ratio of (a) / (b) or vice versa and/or of (a) / (c) or vice versa is formed. The invention also relates to a corresponding method and to a kit for use in this connection.